Urovant Sciences and Genmab reported disappointing clinical trial announcements.

British scientists analyzing data from a widely used Covid-19 symptom-tracking app have found there are six distinct types of the disease, each distinguished by a cluster of symptoms.

Following a mid-stage flop, Ironwood and AbbVie discontinued the development of an experimental drug aimed at the treatment of abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D).

Innovative Health Solutions Inc. announced FDA clearance for the new device IB-Stim to treat functional abdominal pain associated with irritable bowel syndrome (IBS) in patients ages 11-18 years old.